Search Results

Darapladib 10 mg  | 100.00%

TargetMol

Darapladib(IC50=0.25 nM) is a substituted pyrimidone with inhibitory activity towards lipoprotein-associated phospholipase-A2 (Lp-PLA2).

More Information Supplier Page

CP-673451 5 mg  | 99.93%

TargetMol

CP-673451 is a specific inhibitor of PDGFRα/β (IC50: 10/1 nM) with antiangiogenic and antitumor activity and the selectivity is higher 450-fold than other angiogenic receptors.

More Information Supplier Page

CP-673451 50 mg  | 99.93%

TargetMol

CP-673451 is a specific inhibitor of PDGFRα/β (IC50: 10/1 nM) with antiangiogenic and antitumor activity and the selectivity is higher 450-fold than other angiogenic receptors.

More Information Supplier Page

CP-673451 2 mg  | 99.93%

TargetMol

CP-673451 is a specific inhibitor of PDGFRα/β (IC50: 10/1 nM) with antiangiogenic and antitumor activity and the selectivity is higher 450-fold than other angiogenic receptors.

More Information Supplier Page

CP-673451 25 mg  | 99.93%

TargetMol

CP-673451 is a specific inhibitor of PDGFRα/β (IC50: 10/1 nM) with antiangiogenic and antitumor activity and the selectivity is higher 450-fold than other angiogenic receptors.

More Information Supplier Page

CP-673451 10 mg  | 99.93%

TargetMol

CP-673451 is a specific inhibitor of PDGFRα/β (IC50: 10/1 nM) with antiangiogenic and antitumor activity and the selectivity is higher 450-fold than other angiogenic receptors.

More Information Supplier Page

Darapladib 25 mg  | 100.00%

TargetMol

Darapladib(IC50=0.25 nM) is a substituted pyrimidone with inhibitory activity towards lipoprotein-associated phospholipase-A2 (Lp-PLA2).

More Information Supplier Page

Darapladib 2 mg  | 100.00%

TargetMol

Darapladib(IC50=0.25 nM) is a substituted pyrimidone with inhibitory activity towards lipoprotein-associated phospholipase-A2 (Lp-PLA2).

More Information Supplier Page

Darapladib 5 mg  | 100.00%

TargetMol

Darapladib(IC50=0.25 nM) is a substituted pyrimidone with inhibitory activity towards lipoprotein-associated phospholipase-A2 (Lp-PLA2).

More Information Supplier Page

Emtricitabine 500 mg  | 99.91%

TargetMol

Emtricitabine (FTC), a nucleoside reverse transcriptase inhibitor, exhibits inhibition activity against human immunodeficiency virus (HIV) and hepatitis B virus.

More Information Supplier Page